APA (7th ed.) Citation

M, H., P, G., C, D., V, A., E, M., P, A., . . . G, M. (2024). Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study. European heart journal. Cardiovascular pharmacotherapy, 10(3), 184. https://doi.org/10.1093/ehjcvp/pvad100

Chicago Style (17th ed.) Citation

M, Hauguel-Moreau, et al. "Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure, Rationale and Design of the Randomized AFLOAT Study." European Heart Journal. Cardiovascular Pharmacotherapy 10, no. 3 (2024): 184. https://doi.org/10.1093/ehjcvp/pvad100.

MLA (9th ed.) Citation

M, Hauguel-Moreau, et al. "Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure, Rationale and Design of the Randomized AFLOAT Study." European Heart Journal. Cardiovascular Pharmacotherapy, vol. 10, no. 3, 2024, p. 184, https://doi.org/10.1093/ehjcvp/pvad100.